These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36017827)

  • 1. Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial.
    Schurad B; Koch C; Schug B; Morte A; Vaqué A; De la Torre R; Iniesta M
    Curr Alzheimer Res; 2022; 19(7):541-553. PubMed ID: 36017827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared with Exelon in Healthy Subjects.
    Morte A; Vaqué A; Iniesta M; Schug B; Koch C; De la Torre R; Schurad B
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):567-578. PubMed ID: 35696054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
    Dhillon S
    Drugs Aging; 2011 Nov; 28(11):927-30. PubMed ID: 22054233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
    Dhillon S
    Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
    Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
    Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
    Frampton JE
    Drugs Aging; 2014 Aug; 31(8):639-49. PubMed ID: 24989628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
    Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
    Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
    Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
    Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
    Grossberg G; Cummings J; Frölich L; Bellelli G; Molinuevo JL; Krahnke T; Strohmaier C
    Am J Alzheimers Dis Other Demen; 2013 Sep; 28(6):583-91. PubMed ID: 23982674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia.
    Reinhardt F; Scarmeas N; Karan R; Veldandi UK; Modali S; Duvvuri K; Pathan RK
    Curr Alzheimer Res; 2021; 18(4):273-282. PubMed ID: 34279198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
    Grossberg G; Sadowsky C; Fröstl H; Frölich L; Nagel J; Tekin S; Zechner S; Ros J; Orgogozo JM
    Alzheimer Dis Assoc Disord; 2009; 23(2):158-64. PubMed ID: 19484917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
    Pregelj P
    Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.